Related Experiment Video
Updated: Sep 28, 2025

Testing the Role of Multicopy Plasmids in the Evolution of Antibiotic Resistance
Published on: May 2, 2018
Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a
T A Alsenani1, S L Viviani1, V Kumar1
1Department of Biochemistry, Case Western Reserve Universitygrid.67105.35 School of Medicine, Cleveland, Ohio, USA.
Abstract:
Klebsiella pneumoniae carbapenemases (KPC-2 and KPC-3) present a global clinical threat, as these β-lactamases confer resistance to carbapenems and oxyimino-cephalosporins. Recent clinically identified KPC variants with substitutions at Ambler position D179, located in the Ω loop, are resistant to the β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam, but susceptible to meropenem-vaborbactam. To gain insights into ceftazidime-avibactam resistance conferred by D179N/Y variants of KPC-2, crystal structures of these variants were determined. The D179N KPC-2 structure revealed that the change of the carboxyl to an amide moiety at position 179 disrupted the salt bridge with R164 present in wild-type KPC-2. Additional interactions were disrupted in the Ω loop, causing a decrease in the melting temperature. Shifts originating from N179 were also transmitted toward the active site, including ∼1-Å shifts of the deacylation water and interacting residue N170. The structure of the D179Y KPC-2 β-lactamase revealed more drastic changes, as this variant exhibited disorder of the Ω loop, with other flanking regions also being disordered. We postulate that the KPC-2 variants can accommodate ceftazidime because the Ω loop is displaced in D179Y or can be more readily displaced in D179N KPC-2. To understand why the β-lactamase inhibitor vaborbactam is less affected by the D179 variants than avibactam, we determined the crystal structure of D179N KPC-2 in complex with vaborbactam, which revealed wild-type KPC-2-like vaborbactam-active site interactions. Overall, the structural results regarding KPC-2 D179 variants revealed various degrees of destabilization of the Ω loop that contribute to ceftazidime-avibactam resistance, possible substrate-assisted catalysis of ceftazidime, and meropenem and meropenem-vaborbactam susceptibility.
Insights
New Klebsiella pneumoniae carbapenemase (KPC) variants resist ceftazidime-avibactam due to Ω loop destabilization. These KPC variants remain susceptible to meropenem-vaborbactam, offering treatment options.
Area of Science:
- Microbiology
- Structural Biology
- Drug Resistance
Background:
- Klebsiella pneumoniae carbapenemases (KPC) are critical global threats, conferring resistance to vital antibiotics.
- Emerging KPC variants at Ambler position D179 exhibit resistance to ceftazidime-avibactam but remain susceptible to meropenem-vaborbactam.
Purpose of the Study:
- To elucidate the structural basis of ceftazidime-avibactam resistance in KPC-2 variants (D179N/Y).
- To understand the differential impact of D179 variants on avibactam versus vaborbactam inhibition.
Main Methods:
- X-ray crystallography of KPC-2 D179N and D179Y variants, both alone and in complex with vaborbactam.
- Analysis of structural changes in the Ω loop and active site.
Main Results:
- KPC-2 D179N/Y variants show Ω loop destabilization, disrupting interactions crucial for wild-type KPC-2 function.
- Structural data indicate altered Ω loop dynamics facilitate ceftazidime binding/hydrolysis.
- The KPC-2 D179N-vaborbactam complex structure reveals conserved active site interactions, explaining retained susceptibility.
Conclusions:
- Ω loop destabilization in KPC-2 D179 variants is key to ceftazidime-avibactam resistance.
- Meropenem-vaborbactam retains efficacy against these KPC variants due to stable active site interactions.
- Structural insights guide the development of strategies against carbapenemase resistance.

